Immune killer cells (non-small-cell lung cancer, Newmed Life Sciences)

N/A

Report date: 2022/09/06 18:04:08

Base Information

Drug NameImmune killer cells (non-small-cell lung cancer, Newmed Life Sciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cells modulators
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNewmed Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesNewmed Life Sciences
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A